Grants Program - CURE SYNGAP1 supports researchers and clinicians studying SYNGAP1-related disorders, funding research and clinical networks to advance trial readiness and disease-modifying treatments.
Funder: CURE SYNGAP1
Due Dates (Anticipated): August 2027 (LOI / application window deadline)
Funding Amounts: Seed: up to $25,000 once; Trainee: up to $65,000 for one year; Investigator: up to $130,000 for one year; Clinical Network Support: variable amount and duration
Summary: Supports SYNGAP1-related disorder research and clinical networks to accelerate safe, effective disease-modifying treatments, with clinical trial readiness as the current priority.
Key Information: Full proposals are reviewed by invitation only, following a successful one-page Letter of Intent.
CURE SYNGAP1, formerly the SynGAP Research Fund, supports laboratory-based researchers and clinicians studying SYNGAP1-Related Disorders (SRD). The program aims to accelerate safe, effective treatments that meaningfully modify SRD and reduce suffering for patients and families. Support spans proof-of-concept studies, research assets, postdoctoral research, investigator-led studies, and multidisciplinary clinical networks.
Clinical trial readiness is the current funding priority. Focus areas include identifying more people with SRD through genetics, addressing behaviors that put patients and families at risk, and understanding SYNGAP1 functions to clarify where precision medicines need to be delivered. Investigator-funded work has included synaptic and non-synaptic function, protein-protein interactions, drug action in SYNGAP1 models, and translational precision medicine research.